Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MASP2 | O00187 | 1/20 | 0.41 |
| ▸ | GAPDH | P04406 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | JUND | P17535 | 1/20 | 0.41 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20480675 | 0.85 | PSMB5 (0.47) | HTR1AKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL7381949 | 0.83 | MAPT (0.41) | HTR1AKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL20480545 | 0.81 | PTGDR2 (0.45) | HTR1APTGDR2CTNNB1WNT3ACA12 | |
| SCHEMBL10638224 | 0.80 | POLL (0.50) | HTR1AKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL2729875 | 0.80 | ADRA2A (0.47) | HTR1APTGDR2KDM4EALDH1A1 | |
| SCHEMBL27951692 | 0.80 | ADRA2A (0.47) | PTGDR2ALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL1845044 | 0.80 | HTR1A (0.45) | HTR1AALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL20480472 | 0.79 | KDM4E (0.41) | HTR1APTGDR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20480108 | 0.77 | ADRA2A (0.47) | PTGDR2TDP1 | |
| SCHEMBL2838371 | 0.77 | PSMB5 (0.47) | KDM4EALDH1A1HSD17B10LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-10-01 | — | — | US | disclosed |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| EP-1318140-B9 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8198454-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| EP-1318140-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, CLCN2, SCNN1G | HTR1A 3999/4885PTGDR2 1154/4885KDM4E 4044/4885 |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | HTR1A 1942/4885PTGDR2 862/4885KDM4E 4468/4885 |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | HTR1A 3999/4885PTGDR2 1154/4885KDM4E 4044/4885 |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | C5AR1, C5AR2, C1S | HTR1A 1491/4885PTGDR2 716/4885KDM4E 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.